MedTrace Logo

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

NCT01272531 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 560

Last updated 2020-06-09

No results posted yet for this study

Summary

This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.

Conditions

  • Bipolar Affective Disorder

Interventions

DRUG

Mood stabilizer treatment

lithium or valproate

Sponsors & Collaborators

Principal Investigators

  • John R Kelsoe, M.D. · University of California, San Diego

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States
  • Canada
  • Norway

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272531 on ClinicalTrials.gov